Home›Legal›Semaglutide in California
Semaglutide in California: Legal Status & Provider Guide (2026)
Quick Answer
Semaglutide is a prescription substance in the United States. Semaglutide is an FDA-approved drug. Compounded versions were temporarily permitted during a drug shortage that ended in early 2025. Current federal law generally prohibits 503A/503B compounding of semaglutide except for narrow clinical exceptions. Patients should verify their provider's legal basis for offering compounded semaglutide. In California, compounding is governed by the California State Board of Pharmacy (CSBP). California allows nurse practitioners and physician assistants with standardized procedures or physician collaboration to prescribe compounded peptides. California's telehealth laws (AB 2019 and subsequent legislation) require an established patient-provider relationship before prescribing. Out-of-state prescribers cannot prescribe to California patients without a California license.
Federal Legal Status
FDA Approval Status
FDA-approved as Ozempic (type 2 diabetes, 2017), Wegovy (chronic weight management, 2021), and Rybelsus (oral, type 2 diabetes, 2019). Compounded semaglutide was permitted during shortage but FDA declared shortage resolved in March 2025.
Compounding Pharmacy Rules (Federal)
Compounding of semaglutide was broadly permitted under shortage exemptions through early 2025. Following FDA's March 2025 shortage resolution declaration, 503B outsourcing facilities had a wind-down period through April 2025, and 503A pharmacies through May 2025. As of mid-2025, compounded semaglutide is generally prohibited except for specific patient needs (e.g., documented allergy to an inactive ingredient in the commercially available product) under a valid prescription.
Also Known As
Ozempic · Wegovy · Rybelsus
Primary Research Areas
- Weight management
- Type 2 diabetes
- Cardiovascular risk reduction
- Metabolic health
California Pharmacy Board & Compounding Rules
Compounding Overview
The California State Board of Pharmacy enforces strict compounding standards, often exceeding federal minimums. California has its own sterile compounding licensure category and requires all sterile compounding pharmacies to hold a specialty license. California pharmacies must comply with USP 797 (sterile) and USP 795 (non-sterile) standards. The California Medical Board also imposes strict telemedicine prescribing standards that affect peptide clinics operating as telehealth platforms serving California residents.
Notable Rules
- California requires a specialty sterile compounding license in addition to a standard pharmacy license.
- USP 797 and 795 compliance is mandatory for all California-licensed compounding pharmacies.
- The California Medical Board has specific guidance on prescribing practices for "off-label" and compounded medications.
- Out-of-state pharmacies must be licensed by CSBP to ship prescription compounds into California.
- California prohibits prescription dispensing without an established patient-provider relationship in most telehealth contexts.
Prescribing Requirements in California
California allows nurse practitioners and physician assistants with standardized procedures or physician collaboration to prescribe compounded peptides. California's telehealth laws (AB 2019 and subsequent legislation) require an established patient-provider relationship before prescribing. Out-of-state prescribers cannot prescribe to California patients without a California license.
About Semaglutide
Semaglutide is a GLP-1 receptor agonist originally developed by Novo Nordisk. It is FDA-approved for type 2 diabetes and chronic weight management and is among the most studied compounds in contemporary metabolic medicine.
For more research information, mechanism of action, and provider availability, see the Semaglutide research profile on PeptideBase.
Frequently Asked Questions
- Is compounded semaglutide legal in 2026?
- FDA declared the semaglutide shortage resolved in March 2025. After wind-down periods, compounding of semaglutide is generally prohibited for 503A and 503B facilities. Narrow exceptions exist for documented allergies to commercially available formulations. Patients should ask providers for the specific legal basis for any compounded product.
- What is the difference between Ozempic, Wegovy, and compounded semaglutide?
- Ozempic (0.5–2 mg weekly injection) is approved for type 2 diabetes. Wegovy (2.4 mg weekly injection) is approved for chronic weight management. Compounded semaglutide was chemically equivalent but manufactured by compounding pharmacies — a practice now restricted following the shortage resolution.
Semaglutide Providers in California
No providers currently listed in California for Semaglutide. Browse the full directory to find providers offering Semaglutide.
Browse all Semaglutide providers →Semaglutide Legal Status in Other States
Pharmacy board rules and compounding regulations vary by state. Compare Semaglutide legal status across other major markets:
Content review: This educational overview is prepared by the PeptideBase editorial team and reviewed for factual accuracy. Reviewer byline coming soon (gated on 4.4). Last updated: .